sacubitril/valsartan (LCZ696) + enalapril + matching placebo sacubitril/valsartan (LCZ696) + matching placebo enalapril

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Heart Failure, Reduced Ejection Fraction

Conditions

Heart Failure, Reduced Ejection Fraction

Trial Timeline

Dec 16, 2016 → Mar 19, 2018

NCT ID

NCT02970669

About sacubitril/valsartan (LCZ696) + enalapril + matching placebo sacubitril/valsartan (LCZ696) + matching placebo enalapril

sacubitril/valsartan (LCZ696) + enalapril + matching placebo sacubitril/valsartan (LCZ696) + matching placebo enalapril is a approved stage product being developed by Novartis for Heart Failure, Reduced Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT02970669. Target conditions include Heart Failure, Reduced Ejection Fraction.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure, Reduced Ejection Fraction were approved

Approved (20) Terminated (2) Active (0)

✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved

✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved

✅ConivaptanAstellas PharmaApproved

✅RegadenosonAstellas PharmaApproved

✅Regadenoson + GadoliniumAstellas PharmaApproved

✅regadenosonAstellas PharmaApproved

✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02970669	Approved	Completed	Dec 16, 2016	Mar 19, 2018	Heart Failure, Reduced Ejection Fraction

Competing Products

20 competing products in Heart Failure, Reduced Ejection Fraction

See all competitors

Product	Company	Stage	Hype Score
mRNA-0184	Moderna	Phase 1	0
IV diuretic	Nuwellis	Pre-clinical	16
IV Loop Diuretics	Nuwellis	Pre-clinical	23
Stepped pharmacologic care	Nuwellis	Phase 3	30
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	8
TRV120027 + Normal Saline	Trevena	Phase 1	19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	25
TRV120027 + Placebo	Trevena	Phase 1/2	22
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	25
INXN-4001	Precigen	Phase 1	23
LY3461767 + Placebo	Eli Lilly	Phase 1	29
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	43
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	32
Olmesartan	Daiichi Sankyo	Phase 3	40
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	22
Regadenoson	Astellas Pharma	Phase 1	29
Advagraf + Prograf	Astellas Pharma	Phase 2	35